cept Therapeutics rporated(US:CORT) Globenewswire·2026-01-30 16:27Core Insights - Corcept Therapeutics Incorporated is under investigation by Bernstein Liebhard LLP for potential violations of federal securities laws [1][2] - The company received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant, which led to a significant drop in its stock price [3] Company Developments - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness is required for a favorable benefit-risk assessment [3] - Following the FDA's announcement, Corcept's stock price fell by $35.40 per share, representing a 50.42% decline, closing at $34.80 per share [3] Legal Context - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success, indicating a strong capability in handling investor rights cases [4]